Drug
Mecasermin clinical trials
Also written Increlex and insulin-like growth factor I.
- studies test it
- 34
- open now
- 1
- in phase 3
- 8
- first study started
- 1991
Keep track of what changes. Save the mecasermin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Increlex
- 13
Studies by the year they started
33 studies that test it; most in 2011 (7)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1995 | 2 |
| 1997 | 1 |
| 1998 | 1 |
| 2000 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 9
- Phase 2
- 19
- Phase 3
- 8
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 27
Ipsen (5) · Massachusetts General Hospital (4) · Children's Hospital Medical Center, Cincinnati (2) · Icahn School of Medicine at Mount Sinai (2) · Boston Children's Hospital (2) · Children's Hospital of Philadelphia (2) · Bispebjerg Hospital (2) · The University of Texas Medical Branch, Galveston (1)
Often tested with
Tested in the same studies.
Rinfabate (2) · Insulin (1) · Oxandrolone (1) · Propranolol (1) · Growth Hormone (1) · Insulin-Like Growth Factor Binding Protein 3 (1) · Itraconazole (1) · Estradiol (1)
Studies
Open first, then newest update. How each study uses mecasermin is read from its arms, and is right about nine times in ten.
Testing it · 34
- Gene Expression Changes In Young and Geriatric SkinRecruitingEarly Phase 1Wright State UniversityNCT03932162Written as Insulin-Like Growth Factor 1
- Increlex Treatment of Children With Chronic Liver Disease and Short StatureWithdrawnNot applicableUniversity of California, Los AngelesNCT01314508Written as Increlex
- Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk FactorsTerminatedPhase 1/2Columbia UniversityNCT00684957Written as Recombinant Human IGF-1
- IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 DeficiencyCompletedPhase 1/2Children's Hospital Medical Center, CincinnatiNCT02636270Written as Increlex
- A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum DisorderTerminatedPhase 2Icahn School of Medicine at Mount SinaiNCT01970345Written as IGF-1
- Long-Term Treatment With rhIGF-1 in GHISCompletedPhase 2/3IpsenNCT00571727Written as mecasermin
- Assessment of Mechanisms of Improved Wound HealingCompletedPhase 2/3The University of Texas Medical Branch, GalvestonNCT00673309Written as IGF-1/IGFBP-3
- rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 DeficiencyTerminatedPhase 2IpsenNCT00572156Written as Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
- Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)CompletedPhase 2ShireNCT02386839Written as rhIGF-1/rhIGFBP-3
- Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)CompletedPhase 2Icahn School of Medicine at Mount SinaiNCT01525901Written as Insulin-Like Growth Factor-1 (IGF-1)
- Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia NervosaCompletedPhase 2Massachusetts General HospitalNCT00720122Written as Recombinant human insulin like growth factor-1 (rhIGF-1)
- Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in AdolescentsCompletedPhase 1/2Massachusetts General HospitalNCT00516386Written as RhIGF-1
- Effects of Anorexia Nervosa on Peak Bone MassCompletedPhase 3Massachusetts General HospitalNCT01301183Written as RhIGF-1 with transdermal 17-beta estradiol
- Safety and Efficacy Study of IGF-1 in Duchenne Muscular DystrophyCompletedPhase 1/2Children's Hospital Medical Center, CincinnatiNCT01207908Written as IGF-1
- Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 DeficiencyTerminatedPhase 3IpsenNCT00330668Written as rh IGF-1 (mecasermin)
- Patellar Tendinopathy - Effect of Training and Enhancement of the Collagen Synthesis by Insulin-like Growth Factor-IStatus unknownEarly Phase 1Bispebjerg HospitalNCT01834989Written as Insulin-like growth factor I
- Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 DeficiencyCompletedPhase 2/3IpsenNCT00125190Written as rhIGF-1 (mecasermin) for a period of 86 weeks
- IGF-1 and Bone Loss in Women With Anorexia NervosaCompletedNot applicableMassachusetts General HospitalNCT01406444Written as rhIGF-1
- Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) DeficiencyCompletedPhase 3IpsenNCT00125164Written as rhIGF-1 (mecasermin, Tercica, Inc.)
- Treatment of Rett Syndrome With Recombinant Human IGF-1CompletedPhase 2Boston Children's HospitalNCT01777542Written as Recombinant Human Insulin Growth Factor 1 (rhIGF-1)
Codes
What other systems call mecasermin · ClinicalTrials.gg INT000380
- MeSH (NLM) C000604197mecaserminConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7GR9I2683OMECASERMINConfirmed FDA, NLM, Wikidata
- RxNorm 274403Confirmed FDA, Wikidata
- Wikidata Q6804390mecaserminConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2262MecaserminConfirmed FDA, Wikidata
- DrugBank DB01277One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604197 | mecasermin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7GR9I2683O | MECASERMIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 274403 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6804390 | mecasermin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2262 | Mecasermin | Confirmed FDA, Wikidata |
| DrugBank | DB01277 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.